Clinical Trial Update: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation [Phase 3]

View source ↗

Summary

Phase 3 study comparing ASP2215 (gilteritinib) to salvage chemotherapy in adults with relapsed or refractory FLT3-mutated acute myeloid leukemia; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Xospata (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Leukemia, Acute Myeloid (AML) | Phase 3 | Status: COMPLETED | Results posted: 2019-10-17